Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James McCaw

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Epidemics|January 29, 2013
Drivers and consequences of influenza antiviral resistant-strain emergence in a capacity-constrained pandemic responseMathew P Dafilis, Robert Moss, Jodie McVernon, et al.
International Journal of Pharmaceutical Compounding|November 22, 2019
How to Qualify Container Closure Systems for Intended Use, Part 1Amy A Kim, Matthew R Gehrmann, James McCaw, et al.
American Journal of Epidemiology|April 28, 2009
Optimal dosing and dynamic distribution of vaccines in an influenza pandemicJames Wood, James McCaw, Niels Becker, et al.
Science Advances|April 8, 2022
COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2Cameron Zachreson, Freya M Shearer, David J Price, et al.
Communicable Diseases Intelligence (2018)|March 23, 2026
Temporal analysis of respiratory virus epidemics in Victoria over winter 2024Oliver Eales, Katharine Senior, Saras Windecker, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum StrainsTuo Yang, Stanley C Xie, Pengxing Cao, et al.
The Journal of Infectious Diseases|May 11, 2018
Investigating Viral Interference Between Influenza A Virus and Human Respiratory Syncytial Virus in a Ferret Model of InfectionKok Fei Chan, Louise A Carolan, Daniil Korenkov, et al.
Malaria Journal|August 31, 2012
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical developmentSophie Zaloumis, Andrew Humberstone, Susan A Charman, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Epidemics|January 29, 2013
Drivers and consequences of influenza antiviral resistant-strain emergence in a capacity-constrained pandemic responseMathew P Dafilis, Robert Moss, Jodie McVernon, et al.
International Journal of Pharmaceutical Compounding|November 22, 2019
How to Qualify Container Closure Systems for Intended Use, Part 1Amy A Kim, Matthew R Gehrmann, James McCaw, et al.
American Journal of Epidemiology|April 28, 2009
Optimal dosing and dynamic distribution of vaccines in an influenza pandemicJames Wood, James McCaw, Niels Becker, et al.
Science Advances|April 8, 2022
COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2Cameron Zachreson, Freya M Shearer, David J Price, et al.
Communicable Diseases Intelligence (2018)|March 23, 2026
Temporal analysis of respiratory virus epidemics in Victoria over winter 2024Oliver Eales, Katharine Senior, Saras Windecker, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2016
Comparison of the Exposure Time Dependence of the Activities of Synthetic Ozonide Antimalarials and Dihydroartemisinin against K13 Wild-Type and Mutant Plasmodium falciparum StrainsTuo Yang, Stanley C Xie, Pengxing Cao, et al.
The Journal of Infectious Diseases|May 11, 2018
Investigating Viral Interference Between Influenza A Virus and Human Respiratory Syncytial Virus in a Ferret Model of InfectionKok Fei Chan, Louise A Carolan, Daniil Korenkov, et al.
Malaria Journal|August 31, 2012
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical developmentSophie Zaloumis, Andrew Humberstone, Susan A Charman, et al.
Pageof 1